JP7466519B2 - 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム - Google Patents

腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム Download PDF

Info

Publication number
JP7466519B2
JP7466519B2 JP2021503558A JP2021503558A JP7466519B2 JP 7466519 B2 JP7466519 B2 JP 7466519B2 JP 2021503558 A JP2021503558 A JP 2021503558A JP 2021503558 A JP2021503558 A JP 2021503558A JP 7466519 B2 JP7466519 B2 JP 7466519B2
Authority
JP
Japan
Prior art keywords
nucleic acid
mutation
sample
sequencing
tmb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503558A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020023420A5 (https=
JP2021531775A (ja
JP2021531775A5 (https=
Inventor
ケイティ ジュリア クイン，
エレナ ヘルマン，
ダーリヤ チュドヴァ，
ヘルミー エルトーキー，
ジャスティン アイ． オーデガード，
スティーブン フェアクロー，
エリーン シャム，
アリエル ジャイモビッチ，
Original Assignee
ガーダント ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガーダント ヘルス， インコーポレイテッド filed Critical ガーダント ヘルス， インコーポレイテッド
Publication of JP2021531775A publication Critical patent/JP2021531775A/ja
Publication of JPWO2020023420A5 publication Critical patent/JPWO2020023420A5/ja
Publication of JP2021531775A5 publication Critical patent/JP2021531775A5/ja
Priority to JP2024009403A priority Critical patent/JP2024032860A/ja
Application granted granted Critical
Publication of JP7466519B2 publication Critical patent/JP7466519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021503558A 2018-07-23 2019-07-22 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム Active JP7466519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024009403A JP2024032860A (ja) 2018-07-23 2024-01-25 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862702280P 2018-07-23 2018-07-23
US62/702,280 2018-07-23
US201862741770P 2018-10-05 2018-10-05
US62/741,770 2018-10-05
US201862782894P 2018-12-20 2018-12-20
US62/782,894 2018-12-20
US201962824246P 2019-03-26 2019-03-26
US62/824,246 2019-03-26
PCT/US2019/042882 WO2020023420A2 (en) 2018-07-23 2019-07-22 Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024009403A Division JP2024032860A (ja) 2018-07-23 2024-01-25 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム

Publications (4)

Publication Number Publication Date
JP2021531775A JP2021531775A (ja) 2021-11-25
JPWO2020023420A5 JPWO2020023420A5 (https=) 2022-08-01
JP2021531775A5 JP2021531775A5 (https=) 2022-08-01
JP7466519B2 true JP7466519B2 (ja) 2024-04-12

Family

ID=67659956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021503558A Active JP7466519B2 (ja) 2018-07-23 2019-07-22 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム
JP2024009403A Withdrawn JP2024032860A (ja) 2018-07-23 2024-01-25 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024009403A Withdrawn JP2024032860A (ja) 2018-07-23 2024-01-25 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム

Country Status (9)

Country Link
US (3) US11118234B2 (https=)
EP (1) EP3827100A2 (https=)
JP (2) JP7466519B2 (https=)
KR (1) KR20210038577A (https=)
CN (2) CN120193081A (https=)
AU (1) AU2019310041B2 (https=)
CA (1) CA3107983A1 (https=)
SG (1) SG11202100344WA (https=)
WO (1) WO2020023420A2 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
AU2011358564B9 (en) 2011-02-09 2017-07-13 Natera, Inc Methods for non-invasive prenatal ploidy calling
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
WO2017181202A2 (en) 2016-04-15 2017-10-19 Natera, Inc. Methods for lung cancer detection
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
IL319255A (en) 2017-08-07 2025-04-01 Univ Johns Hopkins Methods and materials for cancer assessment and treatment
JP2021506342A (ja) 2017-12-14 2021-02-22 ティーエーアイ ダイアグノスティックス インコーポレイテッドＴａｉ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 移植のための移植片適合性の評価
CA3090426A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
JP7466519B2 (ja) 2018-07-23 2024-04-12 ガーダント ヘルス， インコーポレイテッド 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム
US20200258601A1 (en) * 2018-10-17 2020-08-13 Tempus Labs Targeted-panel tumor mutational burden calculation systems and methods
US10395772B1 (en) 2018-10-17 2019-08-27 Tempus Labs Mobile supplementation, extraction, and analysis of health records
US11640859B2 (en) 2018-10-17 2023-05-02 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
US10957433B2 (en) 2018-12-03 2021-03-23 Tempus Labs, Inc. Clinical concept identification, extraction, and prediction system and related methods
EP4567131A3 (en) * 2019-01-31 2025-09-03 Guardant Health, Inc. Compositions and methods for isolating cell-free dna
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
US11295841B2 (en) 2019-08-22 2022-04-05 Tempus Labs, Inc. Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
US20230114365A1 (en) * 2020-03-26 2023-04-13 Memorial Sloan Kettering Cancer Center Systems and methods for distinguishing pathological mutations from clonal hematopoietic mutations in plasma cell-free dna by fragment size analysis
CN111402952A (zh) * 2020-03-27 2020-07-10 深圳裕策生物科技有限公司 一种检测肿瘤异质性程度的方法及系统
EP4128244A1 (en) * 2020-03-31 2023-02-08 Guardant Health, Inc. Determining tumor fraction for a sample based on methyl binding domain calibration data
CN112116956B (zh) * 2020-09-29 2024-04-19 深圳裕策生物科技有限公司 一种基于二代测序的肿瘤单样本tmb检测方法及装置
US20220411876A1 (en) * 2021-03-05 2022-12-29 Guardant Health, Inc. Methods and related aspects for analyzing molecular response
CN115497556A (zh) * 2021-06-18 2022-12-20 广州燃石医学检验所有限公司 一种用于区分体细胞突变和种系突变的方法
JP2024523401A (ja) * 2021-06-21 2024-06-28 ガーダント ヘルス， インコーポレイテッド コピー数情報に基づく組織起源分析のための方法および組成物
EP4359569A4 (en) * 2021-06-22 2025-02-26 Foundation Medicine, Inc. Systems and methods for evaluating tumor fraction
EP4388091A2 (en) * 2021-08-20 2024-06-26 Guardant Health, Inc. Methods for simultaneous molecular and sample barcoding
WO2023081889A1 (en) * 2021-11-05 2023-05-11 The Johns Hopkins University Methods for treatment of cancer
US20250019770A1 (en) * 2021-11-12 2025-01-16 Foundation Medicine, Inc. Circulating tumor dna fraction and uses thereof
CN114155911A (zh) * 2021-12-08 2022-03-08 深圳基因家科技有限公司 一种矫正肿瘤突变负荷的方法及系统
CN119032182A (zh) * 2022-01-04 2024-11-26 纳特拉公司 用于癌症检测和监测的方法
US20250095771A1 (en) * 2022-01-18 2025-03-20 NEC Laboratories Europe GmbH Methods of vaccine design
EP4567129A3 (en) 2022-02-02 2025-08-13 Guardant Health, Inc. Multifunctional primers for paired sequencing reads
CN114596918B (zh) * 2022-03-11 2023-03-24 苏州吉因加生物医学工程有限公司 一种检测突变的方法及装置
CN116200490B (zh) * 2022-07-25 2025-05-16 慧算基因科技(上海)有限公司 一种实体瘤微小病灶残留检测panel的筛选方法
CN115404275B (zh) * 2022-08-17 2023-07-11 中山大学·深圳 一种基于纳米孔测序技术评估肿瘤纯度的方法
WO2024112643A1 (en) * 2022-11-21 2024-05-30 Foundation Medicine, Inc. Fragmentomics based identification of tumor-specific copy number alteration states in liquid biopsy
JP2026509730A (ja) * 2023-03-13 2026-03-25 グレイル インコーポレイテッド 白血球混入検出
WO2024215498A1 (en) * 2023-04-12 2024-10-17 Foundation Medicine, Inc. Method for detecting patients with systematically under-estimated tumor mutational burden who may benefit from immunotherapy
WO2024238750A2 (en) * 2023-05-17 2024-11-21 Foundation Medicine, Inc. Clonal hematopoiesis burden as a biomarker for immune checkpoint inhibitor response
WO2025049830A1 (en) * 2023-08-30 2025-03-06 Grail, Inc. Identification and exclusion of variants with outlier allele fractions in tumor fraction estimations
US20250084469A1 (en) 2023-09-12 2025-03-13 Guardant Health, Inc. Methods for analyzing nucleic acids using sequence read family size distribution
WO2025064706A1 (en) 2023-09-19 2025-03-27 Guardant Health, Inc. Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
WO2025076452A1 (en) 2023-10-06 2025-04-10 Guardant Health, Inc. Detecting tumor-related information based on methylation status of cell-free nucleic acid molecules
WO2025096757A1 (en) 2023-11-01 2025-05-08 Sana Biotechnology, Inc. Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
WO2025102060A1 (en) * 2023-11-10 2025-05-15 Caris Mpi, Inc. Accurate detection of origin of cell-free nucleic acids
WO2025122662A1 (en) * 2023-12-04 2025-06-12 Tempus Ai, Inc. Systems and methods for detecting somatic variants derived from circulating tumor nucleic acids
WO2025208044A1 (en) 2024-03-28 2025-10-02 Guardant Health, Inc. Methods for cancer detection using molecular patterns
WO2026006432A2 (en) 2024-06-25 2026-01-02 Guardant Health, Inc. Sequencing methods with partitioning
US12467087B1 (en) 2024-06-25 2025-11-11 Guardant Health, Inc. Sequencing methods with partitioning

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
US20050282196A1 (en) 2004-04-30 2005-12-22 Jose Costa Methods and compositions for cancer diagnosis
US20140296081A1 (en) 2013-03-15 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating tumor markers
WO2017151524A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods and systems for evaluating tumor mutational burden
JP2018507682A (ja) 2014-12-31 2018-03-22 ガーダント ヘルス， インコーポレイテッド 疾患細胞不均一性を示す疾患の検出および処置、ならびに通信試験結果のためのシステムおよび方法
JP2018512048A (ja) 2015-02-10 2018-05-10 ザ チャイニーズ ユニバーシティ オブ ホンコン 癌スクリーニング及び胎児分析のための変異検出

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20030017081A1 (en) 1994-02-10 2003-01-23 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
JP3102800B2 (ja) 1994-08-19 2000-10-23 パーキン−エルマー コーポレイション 増幅及び連結反応の共役法
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
US6969488B2 (en) 1998-05-22 2005-11-29 Solexa, Inc. System and apparatus for sequential processing of analytes
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
WO2001023610A2 (en) 1999-09-29 2001-04-05 Solexa Ltd. Polynucleotide sequencing
AU2457701A (en) 1999-12-28 2001-07-09 Brown University Research Foundation Methods and products for tumor immunotherapy using cytokines
WO2002004680A2 (en) 2000-07-07 2002-01-17 Visigen Biotechnologies, Inc. Real-time sequence determination
AU2002359522A1 (en) 2001-11-28 2003-06-10 Applera Corporation Compositions and methods of selective nucleic acid isolation
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US7315019B2 (en) 2004-09-17 2008-01-01 Pacific Biosciences Of California, Inc. Arrays of optical confinements and uses thereof
US7170050B2 (en) 2004-09-17 2007-01-30 Pacific Biosciences Of California, Inc. Apparatus and methods for optical analysis of molecules
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US7282337B1 (en) 2006-04-14 2007-10-16 Helicos Biosciences Corporation Methods for increasing accuracy of nucleic acid sequencing
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
KR20190002733A (ko) 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US11261494B2 (en) * 2012-06-21 2022-03-01 The Chinese University Of Hong Kong Method of measuring a fractional concentration of tumor DNA
GB2533006B (en) 2012-09-04 2017-06-07 Guardant Health Inc Systems and methods to detect copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US9805407B2 (en) 2013-01-25 2017-10-31 Illumina, Inc. Methods and systems for using a cloud computing environment to configure and sell a biological sample preparation cartridge and share related data
PL2981921T3 (pl) 2013-04-03 2023-05-08 Sequenom, Inc. Metody i procesy nieinwazyjnej oceny zmienności genetycznych
HK1222466A1 (zh) 2013-05-10 2017-06-30 Foundation Medicine, Inc 遗传变异分析
RU2698125C2 (ru) 2013-08-19 2019-08-22 Эбботт Молекьюлар Инк. Библиотеки для секвенирования нового поколения
PE20161344A1 (es) 2014-01-02 2016-12-23 Memorial Sloan Kettering Cancer Center Determinantes de respuesta del cancer a la inmunoterapia
US20150292033A1 (en) 2014-04-10 2015-10-15 Dana-Farber Cancer Institute, Inc. Method of determining cancer prognosis
EP3191628B1 (en) * 2014-09-12 2022-05-25 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acids
EP4098278A1 (en) 2014-11-13 2022-12-07 The Johns Hopkins University Checkpoint blockade and microsatellite instability
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CN108352463A (zh) * 2015-10-28 2018-07-31 大日本印刷株式会社 电池用包装材料、电池、电池用包装材料的制造方法和铝合金箔
US10364468B2 (en) 2016-01-13 2019-07-30 Seven Bridges Genomics Inc. Systems and methods for analyzing circulating tumor DNA
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
US10711312B2 (en) * 2016-07-12 2020-07-14 The Regents Of The University Of California Methods for immunotherapy-based treatment and assessment of cancer
US10294518B2 (en) 2016-09-16 2019-05-21 Fluxion Biosciences, Inc. Methods and systems for ultra-sensitive detection of genomic alterations
AU2017339517B2 (en) * 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
CA3046007A1 (en) 2016-12-22 2018-06-28 Guardant Health, Inc. Methods and systems for analyzing nucleic acid molecules
EP3601600A2 (en) 2017-03-31 2020-02-05 MedImmune, LLC Tumor burden as measured by cell free dna
KR102922386B1 (ko) 2017-07-21 2026-02-04 제넨테크, 인크. 암에 대한 치료 및 진단 방법
EP3685386A1 (en) 2017-09-20 2020-07-29 Guardant Health, Inc. Methods and systems for differentiating somatic and germline variants
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
CA3083787A1 (en) 2017-12-01 2019-06-06 Personal Genome Diagnositics Inc. Process for microsatellite instability detection
JP6975350B2 (ja) 2018-05-03 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 腫瘍突然変異量の測定のための代理マーカーおよび方法
WO2019236478A1 (en) 2018-06-04 2019-12-12 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free nucleic acids
JP7466519B2 (ja) 2018-07-23 2024-04-12 ガーダント ヘルス， インコーポレイテッド 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム
US20200258601A1 (en) 2018-10-17 2020-08-13 Tempus Labs Targeted-panel tumor mutational burden calculation systems and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219765A1 (en) 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
US20050282196A1 (en) 2004-04-30 2005-12-22 Jose Costa Methods and compositions for cancer diagnosis
US20140296081A1 (en) 2013-03-15 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating tumor markers
JP2018507682A (ja) 2014-12-31 2018-03-22 ガーダント ヘルス， インコーポレイテッド 疾患細胞不均一性を示す疾患の検出および処置、ならびに通信試験結果のためのシステムおよび方法
JP2018512048A (ja) 2015-02-10 2018-05-10 ザ チャイニーズ ユニバーシティ オブ ホンコン 癌スクリーニング及び胎児分析のための変異検出
WO2017151524A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods and systems for evaluating tumor mutational burden

Also Published As

Publication number Publication date
JP2024032860A (ja) 2024-03-12
EP3827100A2 (en) 2021-06-02
AU2019310041B2 (en) 2025-11-20
US20200370129A1 (en) 2020-11-26
SG11202100344WA (en) 2021-02-25
WO2020023420A2 (en) 2020-01-30
US12291751B2 (en) 2025-05-06
JP2021531775A (ja) 2021-11-25
US11118234B2 (en) 2021-09-14
CN112752854A (zh) 2021-05-04
AU2019310041A1 (en) 2021-02-04
US20220098671A1 (en) 2022-03-31
WO2020023420A3 (en) 2020-02-27
KR20210038577A (ko) 2021-04-07
CN120193081A (zh) 2025-06-24
CA3107983A1 (en) 2020-01-30
US20250250644A1 (en) 2025-08-07
CN112752854B (zh) 2025-03-18

Similar Documents

Publication Publication Date Title
JP7466519B2 (ja) 腫瘍遺伝子変異量を腫瘍割合およびカバレッジによって調整するための方法およびシステム
JP7699261B2 (ja) 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
JP2026012397A (ja) セルフリー核酸の細胞起源を決定するための方法およびシステム
JP2024513668A (ja) 分子応答を分析するための方法および関連する態様
CN117063239A (zh) 用于分析分子响应的方法和相关方面

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240402

R150 Certificate of patent or registration of utility model

Ref document number: 7466519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150